country

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-132610

Copy Link Print Information

Givosiran

(Synonyms: ALN-AS1)

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

Givosiran (ALN-AS1) is a small interfering RNA that targets hepatic aminolevulinate synthase 1 (ALAS1) messenger RNA. Givosiran downregulates ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid (ALA) and porphobilinogen (PBG) levels. Givosiran demonstrates potent inhibitory activity against ALAS1 in mouse, rat, and cynomolgus monkey models. Givosiran can be used for the research of acute hepatic porphyria (AHP).

For research use only. We do not sell to patients.

Purity: 94.21%
CAS No.: 1639325-43-1
Molecular Weight:16300.60

Storage:

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Givosiran Chemical Structure

CAS No.: 1639325-43-1

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vivo
- Sequence
Chemical Information
Publications (1)
Purity & Documentation
References
Calculators
Help & FAQs
Bioz

Biological Activity

Description

In Vivo

Givosiran (10 mg/kg, s.c., single dose) effectively reduces ALAS1 mRNA levels in liver tissue and serum in rats with rapid onset and long-lasting inhibitory properties^[2].
Givosiran (3 mg/kg, s.c., twice weekly for 3 weeks) exhibits complete preventive effect in the rat acute intermittent porphyria (AIP) model^[2].
Givosiran (20 mg/kg, s.c., single dose) works faster and has stronger inhibition than standard Hemoglobin (HY-P2995) treatment in mice^[2].
Givosiran (1-10 mg/kg, s.c., single dose or once daily for 8 weeks) reduces serum and urinary ALAS1 levels in cynomolgus monkey, and repeated administration results in sustained inhibition that is reversible after drug discontinuation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

AIP model induced by Phenobarbital established in SD rats^[2]
Dosage:

3 mg/kg
Administration:

Subcutaneous injection (s.c.), twice weekly for 3 weeks
Result:

Completely prevented inducible ALAS1 elevation and associated metabolite accumulation.

Animal Model:

AIP model induced by Phenobarbital established in T1/T2 AIP mice^[2]
Dosage:

20 mg/kg
Administration:

Subcutaneous injection (s.c.), single dose
Result:

Inhibited ALAS1 faster and stronger than Hemoglobin.

Animal Model:

AIP model induced by Phenobarbital established in cynomolgus monkey (M. fascicularis)^[2]
Dosage:

1 and 10 mg/kg (single dose); 5 mg/kg (8 weeks)
Administration:

Subcutaneous injection (s.c.), single dose or once daily for 8 weeks
Result:

Dose-dependently and reversibly inhibited ALAS1 levels and repeated dosing achieved sustained suppression.

Sequence

RNA, (Cm-sp-Am-sp-Gm-Am-Am-Am-(2'-deoxy-2'-fluoro)G-Am-(2'-deoxy-2'-fluoro)G-Um-(2'-deoxy-2'-fluoro)G-Um-(2'-deoxy-2'-fluoro)C-Um-(2'-deoxy-2'-fluoro)C-Am-Um-Cm-Um-Um-Am), 3'-[[(2S,4R)-1-[29-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]- 14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]-1,12,19,25-tetraoxo-16-oxa13,20,24-triazanonacos-1-yl]-4-hydroxy-2-pyrrolidinyl]methyl hydrogen phosphate], complex with RNA (Um-sp-(2'-deoxy-2'-fluoro)A-sp-(2'-deoxy-2'-fluoro)A-(2'-deoxy-2'-fluoro)G-Am-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)A-Gm-(2'-deoxy-2'-fluoro)A-Cm-(2'-deoxy-2'-fluoro)A-Cm-(2'-deoxy-2'-fluoro)U-Cm-(2'-deoxy-2'-fluoro)U-Um-(2'-deoxy-2'-fluoro)U-Cm-(2'-deoxy-2'-fluoro)U-Gm-sp-Gm-sp-Um) (1:1)

Chemical Information

CAS No. 1639325-43-1
Appearance Solid
Molecular Weight 16300.60
Color White to off-white
SMILES

[Givosiran]
Synonyms

ALN-AS1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (1)

All Others

Sort by:

Journal Impact Factor

Am J Reprod Immunol

Active Heme Metabolism Suppresses Macrophage Phagocytosis via the TLR4/Type I IFN Signaling/CD36 in Uterine Endometrial Cancer. [Abstract]

2024 Aug;92(2):e13916. PMID: 39166450

Givosiran purchased from MedChemExpress. Usage Cited in: Am J Reprod Immunol. 2024 Aug;92(2):e13916. [Abstract]

Heme concentrations in the RL95-2 cells treated by succinate 2.5 mM for 24 h, then the supplement of 5 µM SDHB inhibitor (Fluopyam) or 1 µM ALAS1 inhibitor (Givosiran) for 24 h.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2242 KB)

References

[1]. Scott LJ. Givosiran: First Approval. Drugs. 2020 Feb;80(3):335-339. [Content Brief]

[2]. Chan A, et al. Preclinical Development of a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating RNA Quantification. Mol Ther Nucleic Acids. 2015 Nov 3;4(11):e263. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass

Concentration

Volume

Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

100 mg

Get Quote In-stock

Price: USD 0.00

Biological Activity
- Description
- In Vivo
- Sequence
Chemical Information
Purity & Documentation
References

RNA, (Cm-sp-Am-sp-Gm-Am-Am-Am-(2'-deoxy-2'-fluoro)G-Am-(2'-deoxy-2'-fluoro)G-Um-(2'-deoxy-2'-fluoro)G-Um-(2'-deoxy-2'-fluoro)C-Um-(2'-deoxy-2'-fluoro)C-Am-Um-Cm-Um-Um-Am), 3'-[[(2S,4R)-1-[29-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]- 14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]-1,12,19,25-tetraoxo-16-oxa13,20,24-triazanonacos-1-yl]-4-hydroxy-2-pyrrolidinyl]methyl hydrogen phosphate], complex with RNA (Um-sp-(2'-deoxy-2'-fluoro)A-sp-(2'-deoxy-2'-fluoro)A-(2'-deoxy-2'-fluoro)G-Am-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)A-Gm-(2'-deoxy-2'-fluoro)A-Cm-(2'-deoxy-2'-fluoro)A-Cm-(2'-deoxy-2'-fluoro)U-Cm-(2'-deoxy-2'-fluoro)U-Um-(2'-deoxy-2'-fluoro)U-Cm-(2'-deoxy-2'-fluoro)U-Gm-sp-Gm-sp-Um) (1:1)

1/16
1/16

Givosiran purchased from MedChemExpress. Usage Cited in: Am J Reprod Immunol. 2024 Aug;92(2):e13916. [Abstract]

Customer Validation
Heme concentrations in the RL95-2 cells treated by succinate 2.5 mM for 24 h, then the supplement of 5 µM SDHB inhibitor (Fluopyam) or 1 µM ALAS1 inhibitor (Givosiran) for 24 h.

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity: